{"ticker": {"uuid": "e6bc52d4-759d-4082-a252-e3fd6873465d", "symbol": "JSPR", "name": "Jasper Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake", "summary": "Entities affiliated with Millennium Management have reported a 1.7% equity stake in Jasper Therapeutics (NASDAQ: JSPR), beneficially owning up to 486,933 shares of its voting common stock as of June 30, 2026. This disclosure was made via a Schedule 13G/A SEC filing, indicating pa", "url": "https://www.stocktitan.net/sec-filings/JSPR/schedule-13g-a-jasper-therapeutics-inc-amended-passive-investment-dis-45db470fade4.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:10:52", "published_display": "10 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "This article provides financial information for Jasper Therapeutics, Inc. (NASDAQ: JSPRW), specifically focusing on its price-to-earnings forward metric. The content includes a brief overview of the company's financial data as presented on TradingView. It appears to be a stub or ", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T08:40:26", "published_display": "09 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics stock holds the focus. Company profile stays central.", "summary": "Jasper Therapeutics (JSPR) is a clinical-stage biotechnology company listed on Nasdaq, with its stock performance currently driven by its company profile and development pipeline. The lead program, briquilimab, focuses on antibody-based therapies for immune-mediated diseases, par", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/jasper-therapeutics-stock-holds-the-focus-company-profile-stays-central/69713403", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T11:42:08", "published_display": "07 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "The article discusses the enterprise value to EBIT forward for Jasper Therapeutics, Inc. (NASDAQ:JSPRW) as presented on TradingView. It appears to be a financial data page rather than a detailed analysis. The content primarily lists navigation and platform features, indicating a ", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T13:39:20", "published_display": "06 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "This article provides the \"Price to sales forward\" metric for Jasper Therapeutics, Inc. (NASDAQ:JSPRW) on TradingView. It indicates that the market is closed with no trades and lists various sections typical of a financial data platform. The content is mostly boilerplate from a f", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:39:47", "published_display": "04 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JSPR - Jasper Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Jasper Therapeutics Inc (JSPR), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $0.4283, experiencing a 5.76% decre", "url": "https://finviz.com/stock?t=JSPR&ty=oc&p=m&b=1&ov=chain_date&e=2026-10-16", "source_name": "Finviz", "published_at": "2026-07-03T15:38:57", "published_display": "03 Jul 2026 15:38", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics focuses on gene-based therapies as investors assess its Nasdaq-listed stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZkQ5RHNmclgyWkotbko1aEhyMUdIT3FXSkNXZ2NranFsQ3Z6MmRkZHBhdXJqZ1BOU1AzVWV3M1hva29HRGVIc3dQMmF1aXR1OFlObkJMR216ZUI4eDNkTW5lbURVZ0xVaDRpcmNpYXF0QWZ2LXY1WmpjOS1KSkswcFIwMlZaTmFrMlR2ZFJPSm0xVzNEVE9FNS12N296SDVzdF9lS3dxV0hiaTBSc2xKYjJpT04yT3VVTjBxNUZhZ2hieGpsVUxHUVd3?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPR", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQeVlndnBnZThHOTYyeVhyMXJTYi00akk1SFlOdFh5eEt0WkJ4bnFUa1pxTF9rX2tHbzhyLXMxZndWM3lGTW5tZV9ESWc0M1NDVWlVbU1wZzZpWjBzUFdwVWFuLXJTeGVjNzlmUkFEbm1xU013cXN0WW9QYjk2UXhkclRiR3NrOVB2dm1TNWpFVHczek1EX0l4cTBvTWk?oc=5", "source_name": "TradingView", "published_at": "2026-07-03T06:55:38+00:00", "published_display": "03 Jul 2026 06:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPR", "summary": "This page provides financial data, specifically the \"Price to sales forward\" metric, for Jasper Therapeutics, Inc. (NASDAQ: JSPR). The content appears to be a financial data presentation or a module within a larger financial platform like TradingView, with information about the s", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T07:09:30", "published_display": "03 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPR", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Jasper Therapeutics, Inc. (NASDAQ: JSPR) on TradingView. It shows the company's financial data, though the specific value for the metric is not provided in the snippet. The page indicates trading activity ", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T13:40:44", "published_display": "02 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japer Therapeutics, Inc.Warrant 2021-01.12.26 on Jasper Therapeutics Financial Disclosures & SEC Filings", "summary": "This article provides a listing of Jasper Therapeutics, Inc.'s SEC filings and other key documents, including earnings reports, corporate presentations, and study results for its briquilimab drug candidate. The documents reveal strong clinical progress in treatments for condition", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T09:39:44", "published_display": "02 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "This article displays financial information for Jasper Therapeutics, Inc. (NASDAQ: JSPRW), specifically its enterprise value to revenue forward. The content appears to be a stub or a section within a larger financial data platform like TradingView, with a focus on providing speci", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T08:39:44", "published_display": "02 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$287k As Jasper Therapeutics Drops", "summary": "Insiders at Jasper Therapeutics (NASDAQ:JSPR) who bought US$347.5k worth of stock at an average price of US$2.43 have seen their investment drop significantly to US$60.0k after a 14% decrease in the stock price. Despite these recent losses, the fact that insiders purchased shares", "url": "https://www.sahmcapital.com/news/content/insider-traders-lose-us287k-as-jasper-therapeutics-drops-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-01T04:09:27", "published_display": "01 Jul 2026 04:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Jasper Therapeutics, Inc. (NASDAQ:JSPR) for alleged federal securities law violations. The lawsuit claims that Jasper made materially false and misleading statements regarding its manufacturing contro", "url": "https://natlawreview.com/press-releases/jspr-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-jasper", "source_name": "The National Law Review", "published_at": "2026-06-29T14:39:44", "published_display": "29 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Jasper Therapeutics, Inc. \u2013 BOATS:JSPRW", "summary": "This article provides the \"price to earnings forward\" value for Jasper Therapeutics, Inc. (JSPRW). It focuses solely on this financial metric without offering additional analysis or context. The content is presented within the framework of financial data provided by TradingView.", "url": "https://www.tradingview.com/symbols/BOATS-JSPRW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:40:19", "published_display": "26 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Stock - Analyst consensus and weekly review", "summary": "This article provides an analyst consensus and weekly review for Jasper Therapeutics (JSPR), a speculative small-cap biotech. It highlights the company's \"Buy\" rating profile from analysts, despite its early-stage pipeline and limited revenue, focusing on future clinical mileston", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/jasper-therapeutics-stock-analyst-consensus-and-weekly-review/69586016", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T23:01:35", "published_display": "19 Jun 2026 23:01", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article from TradingKey analyzes the financial health of Jasper Therapeutics Inc (JSPRW) by examining its profitability and balance sheet. However, the report notes that relevant financial data for key metrics such as cash and cash equivalents, total assets, total liabilitie", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jsprw/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T11:40:19", "published_display": "19 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Jasper Therapeutics Inc (JSPR), including analyst ratings, target prices, and EPS expectations. Based on 8 analysts, the stock has a \"Buy\" rating with a target price of $10.50, representing a significant upside. The company's previou", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T09:10:35", "published_display": "19 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Institutional Confidence", "summary": "This article provides details on the institutional confidence for Jasper Therapeutics Inc (JSPR), including top institutional shareholders and changes in their holdings. Key holders like Velan Capital, Morgan Stanley, and Millennium Management are listed with their share counts a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T02:40:50", "published_display": "19 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Jasper Therapeutics Inc (JSPR), focusing on key financial metrics like P/E, P/B, P/S, and P/CF ratios. The report indicates that relevant data for these metrics have not yet been disclosed by the company. It also includes current sto", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:40:51", "published_display": "19 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Jasper Therapeutics Inc's (JSPRW) dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years and currently shows no records of stock split events. The current stock price ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jsprw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:39", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPRW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Jasper Therapeutics Inc (JSPRW), showing a previous score of 0.00 with no change. It lists several institutional shareholders and their shareholdings, including changes in their positions. The primary focus i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jsprw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:19", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Jasper Therapeutics Inc's (JSPR) dividend and stock split history. It notes that the company has not distributed dividends in the past five years and details a 10-to-1 merger-related stock split that occurred on January 2, 2024. The stock info", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T08:10:51", "published_display": "17 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes", "summary": "Jasper Therapeutics (JSPR) will hold its 2026 annual stockholder meeting virtually on July 31, 2026. Key proposals include the election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and ", "url": "https://www.stocktitan.net/sec-filings/JSPR/def-14a-jasper-therapeutics-inc-definitive-proxy-statement-e0b6f5fee069.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:39:31", "published_display": "15 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice", "summary": "Jasper Therapeutics (JSPR) has received a Nasdaq notice for falling below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 days, until November 30, 2026, to regain compliance, with its stock continuing to trade without immediate impact. Failure to", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JSPR/pressreleases/2409077/jasper-therapeutics-receives-nasdaq-minimum-bid-price-notice/", "source_name": "The Globe and Mail", "published_at": "2026-06-10T15:56:00", "published_display": "10 Jun 2026 15:56", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value", "summary": "Jasper Therapeutics, a clinical-stage biotechnology company, has announced that its Board of Directors is initiating a comprehensive review of strategic alternatives to maximize shareholder value. These alternatives include potential asset sales, licensing, collaborations, a comp", "url": "https://www.globenewswire.com/news-release/2026/6/1/3304277/0/en/jasper-therapeutics-announces-exploration-of-strategic-alternatives-to-maximize-shareholder-value.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T05:11:13", "published_display": "10 Jun 2026 05:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate", "summary": "This \"Deal Dispatch\" article covers recent M&A activities and company news, including Jasper Therapeutics exploring strategic alternatives, private equity firm New Mountain Capital acquiring Asset Living for over $2 billion, and Robinhood's completion of its $180 million acquisit", "url": "https://www.benzinga.com/m-a/26/06/53036552/deal-dispatch-jasper-therapeutics-for-sale-robinhood-completes-180-million-wonderfi-acquisition-long-john-silvers-franchisee-to-liquidate", "source_name": "Benzinga", "published_at": "2026-06-05T17:09:55", "published_display": "05 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNNDdwUjdOeTJJcG1MQ2Nlc0w1V3oyRFRQT3JCRzZ6WjZMR2lRZnpkNFFqVlB4ZkFFX0VzdWJXM3B1ZVptWE9UVndYLWQ0NkxQQW4yWC0xXzljTXNrMW04WlMzcldEWUluZUpMSlVlbFotMzJ2b2Y1TE1Td1VHU19fd0llZGh5d2E0eWdoMGJ2RnRXQ0lEanlCaUZJeGlMZw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1", "summary": "Jasper Therapeutics (Nasdaq: JSPR) has launched a strategic review to explore options such as asset sale/licensing, collaborations, company sale, mergers, or an orderly wind-down, aiming to maximize shareholder value. The company will also implement cost-saving measures and conti", "url": "https://www.minichart.com.sg/2026/06/01/jasper-therapeutics-initiates-strategic-alternatives-review-to-maximize-shareholder-value-amid-mast-cell-disease-therapy-focus-1/", "source_name": "Minichart", "published_at": "2026-06-01T15:47:00", "published_display": "01 Jun 2026 15:47", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jasper-therapeutics-explores-sale-merger-124908303.html", "source_name": "MT Newswires", "published_at": "2026-06-01T12:49:08+00:00", "published_display": "01 Jun 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Jasper Therapeutics weighs options from asset sale to wind-down", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQT1NkZ0ttTDRuNlN4ZWlBRk9ZYzVITXkzRERxMC1wYmlPaW5LOXFIUkZjUkFDZEY0YWpxMUg5S2pfdTdKRGprZmlyc1lxblYwODB4c3g5d3h6cnpXMEh6WEU4Z2stbFRGVmhyXzNmZWtNdFFyRXAwd3A3T0ZxS2dzQmMxRFB2VDMweE9EY3hBbjdNbkNabG5UeTNaWDl4Y2xGUUJUWWQtNldKa0dOUFRiTk9IUHdWM2U4U05uUEVSNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics explores strategic alternatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQY0ZkX1JwdVJkQVZVMUpOS2k5a3Nad0Y2UTVIb1Rob2x4OHFRc0hVQ2NPelEzZ0lpbC1YMjBNZF9YN1ZfQ1pwWjhkejBhOEhpdDdwb3ZKZ2lDU2llR1dha3JhenRqaHlZTGhYdU43TWFHSXZxcEhRc1l4SkhwRFJaamthVFZxTzd3REJMOW1SRG5jTDRJbndJU1hhM0hJSUpsMnAxS096bHF1QjRH?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-cuts-price-target-jasper-115804345.html", "source_name": "MT Newswires", "published_at": "2026-05-15T11:58:04+00:00", "published_display": "15 May 2026 11:58", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Downgrades Jasper Therapeutics to Hold From Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-downgrades-jasper-therapeutics-112203153.html", "source_name": "MT Newswires", "published_at": "2026-05-15T11:22:03+00:00", "published_display": "15 May 2026 11:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $9.08, Implies 847% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPa1B4RnZpbnU1bkRLb29OSTdOaDI1ZW52d3d1SjRLcGNQSjhRQ2NZeGJqTlhlcnZFMkQxRW44R0w1Mi03Mm1JVFlVdGRmbHAwVEtkTlR2d0I2MGNwOGkxZlAwQjIwU2tvSzBxbjFlOV9ZbGtIMFRXRDk4ZUVERk02MDFLa1ZxQ0EwME5oZGkxRk13SnNJTXFwN0gyVlZhMDVWQ3gza1I5TWNMSGtHbm01UUd5RFVJWkt3a0dPY3A0N1pPamJ3Y1pZTnRTdTVGWFdQd0wtTEFuRFBuVVRQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jasper-therapeutics-reports-first-quarter-200500117.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVWkybk56d1cyQm5xdF95eWc4QTcxSmdqLVh4YXZwLUxXNzg2UDVCbDdQQWU3UlNfakhJZ1hJb1Ywb2JkTDhReXVkQ0tWeFc0XzlDdWo5SUdqd2V3OHVoZlVma2s2YUE1RnI0akZEdmsxNEZMdTJaZkl6OEJNcE1UWkYzaU5kelVBcmRiNmtqNWZ3Y0VSdXZseGpCV0xhem9xTEVV?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Jasper Therapeutics stock rating on CEO change", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNUzBadkpycVRraDB6dTNrZDVXMnJ1bVhrZnYxU0FIZTZ0THcwZWhtNzctc3VEMk1hVlhCYmNONjIzb2UxSGpJOXFFRGlMZjduWDhiN2VJZ3ZyMXc4QnlNUk4tVG0wc1JYdHNhSVZ1MUppY2taWkRtNm5NdGYxWG5LWVozVV9PRTdaU3ljSEl2bnlKNGQzRHpXR3IwTHk5VV91cURyOU1pLWdQTzliRUJ5MG8xSGVXeTc5M0ZLSGVKSkRCc0ND?oc=5", "source_name": "Investing.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPbWcybXJ4aHcwRlRhZThtX2R4Y3NqSk1JbHpHbllKVERwQWhDZGRsdURZVXFJUVp2LUtJX2o2V2JUNWNhQXhFWktRQy0taDZRVG9pUTZvSmc0NkU2QWcwMkJGYkFfS01EZlVPQjNyUlV4dWNzZ3JzUWdCOTNlV0swdktsdGRpUmc5WG5iakYwbHJsUDVCLUIyUTdDak94d2c1aTdhZTNDS3Q1eThucUxIRg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPTk45cFpkTlIyZFp6dmxjQjBTNGtJa2VGcTVWUTEtLVIzUVQ3d2k1bW1uSFJYc2xjMExaRWQ5UWhOUGI3QWkyQVg0TldlalAxZVQ3TDdMdnF2YzBOeGE3ZkNVTk4xQWEwV1NWc1BIMjZBNms2cE5uZHdzd05HcWh4eVVNYy1NZTVCX0FnYUppNndWM2JTMWZ2RzJsbDg3SF9NdEVBT0pZQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow (NASDAQ:JSPR) 2026-01-11", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcGxnbVhtM0pCV09iWVNaR1RMOEcxd0M0T0VMVjNwMDh2TW1qalIzRldUb21USjdxcG9ZS2NnUHpIWnA5cGROR0NnZ1dhTC1zTnVXQVZOZmNpbjhpQ2ZwVFlUU0kxcVhsZE1aanZtR3J2OFBULU90TnRXYXZmLXRfaXUyd1VSMHdTTk1lOXU3NGJURzR3VzhQYTR1NG52bEhUeGdSRmVjdzhUQnNTZEdKREc4YW9ObjRNOWFPUnVKVW9PWVNZQkJLOQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxQMmx1cFZ3YXV2cHlKeFk5RGlwZHhxODdOeXFsYTk0TE1zaXRFQ3RZRVUtV28wUzI0ckQ0UVBPaVh4RTgwX1pRNE9mRXFOR1FWcGJsMHVaT2dfeU5nTzZ1U200blJRLTBxOGN5S3BqMXo5Ull0ZVEwQXlQZ3dNSlBQX1pST3BBd2ZkODFsZ09CWUllSF9iT3BzWjRjbzdQd2ZUNU5GR2lMcUVtMHhnbkJmYy0xSXdacXJxbkRSbS1VMll4WHNEeWhfRHNtcGt4NWJIM25zSXpneUlpYVptWEZacjlVSGd1UmhLc01vMXpPejFFUWtYR1pmbWZoWExaSFdsUnNfTA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Faces A Funding Crunch Before Its Next Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE41QzVmaFpPQ0xKa0xPMnBBRTNfeWRRVzAyMWJlQk5WRFZHeWVucjYzX1l3SkFpc0pEd215SlVhVzk1MWk1OUtoN1poQ2dfVWdGN1Z1M0FpczZURTgx?oc=5", "source_name": "Finimize", "published_at": "2025-12-04T14:29:34+00:00", "published_display": "04 Dec 2025 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNOXp3OXIyMDVIdVFXaEZ3anEzUEhCV1d4UnZnOXdoTmR1T3ZVVkVCc29pemlUWVNLaTE3U1pGUmg2ajBtM04xcEdPMlFKZ2IwQ1F3dUxtTm5pb3FnX0FnY3BfMFFiRUR2Zng5SkZ1Vk5kUkJhZlJjWlM5R1RrNFBwNWRzVlhxUzM5cmRJQnBUdExGcGFZVGwxcXlQYTNQNkdnbFYzRHhqT2ZWOWhRWElSWGRCQWdOSlRWTjJ6aGhMZDdKbmpEYW4xVi1RNlB4blFvc1BXeXY1algzVFI5eFlsTnJieUxzc1lBZjhrdTNGZlRCc3hhUll1UTNQd0htczNIVmc?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics falls after $30 mln stock-and-warrants deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNVS00SDJVZVdRTmZiV1Bybms2V3l0RzlDM05EdUtveUtTR20tZmxUaHpZQ2J6WEFoT3Y3VEhHUUdGWVdmU2preEF2QW9VZDIyRXl2dG9MbWluLTZxb2UxNVVIblEzREloS0VoblBEemlCX25kS3E1d1NqZEhnRFpkblZjeVlVZlRFUmxZQ2JnaWVjQWhwUW96YXFiTXdtMEt3M0RORUZmelM0ZUVNSm9PeGk3RGE1bG1nRFBTT2hRWmc4SnA2YzI0Ql9ncnI?oc=5", "source_name": "TradingView", "published_at": "2025-09-19T07:00:00+00:00", "published_display": "19 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics (JSPR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE4zc0NUNVB0dU95ZHRFRG1tVE9NTWxkNmJxaHl5c2pjZndYZ0tzS0UtTWd4OVhiTmJEOXppQ3ljcEZUZ3lKOXRLZFBTRUVhWWJmVGpz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:34:25+00:00", "published_display": "25 Apr 2025 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics (JSPR) Stock Price, News & Analysis $JSPR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1GVHpSWXNpd2hxRTBEMm10c09UZ1JHV05yX2FhMXVDTGZYT2ZwMkhzVkc0MVo1SXFSSUsxMHllcjE1dldJY0prVUJjbEJ0TmFPT0pTcUlGYU9qdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-09-30T11:53:08+00:00", "published_display": "30 Sep 2021 11:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake", "summary": "Entities affiliated with Millennium Management have reported a 1.7% equity stake in Jasper Therapeutics (NASDAQ: JSPR), beneficially owning up to 486,933 shares of its voting common stock as of June 30, 2026. This disclosure was made via a Schedule 13G/A SEC filing, indicating pa", "url": "https://www.stocktitan.net/sec-filings/JSPR/schedule-13g-a-jasper-therapeutics-inc-amended-passive-investment-dis-45db470fade4.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:10:52", "published_display": "10 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "This article provides financial information for Jasper Therapeutics, Inc. (NASDAQ: JSPRW), specifically focusing on its price-to-earnings forward metric. The content includes a brief overview of the company's financial data as presented on TradingView. It appears to be a stub or ", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T08:40:26", "published_display": "09 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics stock holds the focus. Company profile stays central.", "summary": "Jasper Therapeutics (JSPR) is a clinical-stage biotechnology company listed on Nasdaq, with its stock performance currently driven by its company profile and development pipeline. The lead program, briquilimab, focuses on antibody-based therapies for immune-mediated diseases, par", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/jasper-therapeutics-stock-holds-the-focus-company-profile-stays-central/69713403", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T11:42:08", "published_display": "07 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "The article discusses the enterprise value to EBIT forward for Jasper Therapeutics, Inc. (NASDAQ:JSPRW) as presented on TradingView. It appears to be a financial data page rather than a detailed analysis. The content primarily lists navigation and platform features, indicating a ", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T13:39:20", "published_display": "06 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "This article provides the \"Price to sales forward\" metric for Jasper Therapeutics, Inc. (NASDAQ:JSPRW) on TradingView. It indicates that the market is closed with no trades and lists various sections typical of a financial data platform. The content is mostly boilerplate from a f", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T08:39:47", "published_display": "04 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JSPR - Jasper Therapeutics Inc Options", "summary": "This article provides a detailed financial overview of Jasper Therapeutics Inc (JSPR), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $0.4283, experiencing a 5.76% decre", "url": "https://finviz.com/stock?t=JSPR&ty=oc&p=m&b=1&ov=chain_date&e=2026-10-16", "source_name": "Finviz", "published_at": "2026-07-03T15:38:57", "published_display": "03 Jul 2026 15:38", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics focuses on gene-based therapies as investors assess its Nasdaq-listed stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPZkQ5RHNmclgyWkotbko1aEhyMUdIT3FXSkNXZ2NranFsQ3Z6MmRkZHBhdXJqZ1BOU1AzVWV3M1hva29HRGVIc3dQMmF1aXR1OFlObkJMR216ZUI4eDNkTW5lbURVZ0xVaDRpcmNpYXF0QWZ2LXY1WmpjOS1KSkswcFIwMlZaTmFrMlR2ZFJPSm0xVzNEVE9FNS12N296SDVzdF9lS3dxV0hiaTBSc2xKYjJpT04yT3VVTjBxNUZhZ2hieGpsVUxHUVd3?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPR", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQeVlndnBnZThHOTYyeVhyMXJTYi00akk1SFlOdFh5eEt0WkJ4bnFUa1pxTF9rX2tHbzhyLXMxZndWM3lGTW5tZV9ESWc0M1NDVWlVbU1wZzZpWjBzUFdwVWFuLXJTeGVjNzlmUkFEbm1xU013cXN0WW9QYjk2UXhkclRiR3NrOVB2dm1TNWpFVHczek1EX0l4cTBvTWk?oc=5", "source_name": "TradingView", "published_at": "2026-07-03T06:55:38+00:00", "published_display": "03 Jul 2026 06:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPR", "summary": "This page provides financial data, specifically the \"Price to sales forward\" metric, for Jasper Therapeutics, Inc. (NASDAQ: JSPR). The content appears to be a financial data presentation or a module within a larger financial platform like TradingView, with information about the s", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T07:09:30", "published_display": "03 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPR", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Jasper Therapeutics, Inc. (NASDAQ: JSPR) on TradingView. It shows the company's financial data, though the specific value for the metric is not provided in the snippet. The page indicates trading activity ", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T13:40:44", "published_display": "02 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japer Therapeutics, Inc.Warrant 2021-01.12.26 on Jasper Therapeutics Financial Disclosures & SEC Filings", "summary": "This article provides a listing of Jasper Therapeutics, Inc.'s SEC filings and other key documents, including earnings reports, corporate presentations, and study results for its briquilimab drug candidate. The documents reveal strong clinical progress in treatments for condition", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/documents/", "source_name": "TradingView", "published_at": "2026-07-02T09:39:44", "published_display": "02 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Jasper Therapeutics, Inc. \u2013 NASDAQ:JSPRW", "summary": "This article displays financial information for Jasper Therapeutics, Inc. (NASDAQ: JSPRW), specifically its enterprise value to revenue forward. The content appears to be a stub or a section within a larger financial data platform like TradingView, with a focus on providing speci", "url": "https://www.tradingview.com/symbols/NASDAQ-JSPRW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T08:39:44", "published_display": "02 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$287k As Jasper Therapeutics Drops", "summary": "Insiders at Jasper Therapeutics (NASDAQ:JSPR) who bought US$347.5k worth of stock at an average price of US$2.43 have seen their investment drop significantly to US$60.0k after a 14% decrease in the stock price. Despite these recent losses, the fact that insiders purchased shares", "url": "https://www.sahmcapital.com/news/content/insider-traders-lose-us287k-as-jasper-therapeutics-drops-2026-06-30", "source_name": "Sahm", "published_at": "2026-07-01T04:09:27", "published_display": "01 Jul 2026 04:09", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Jasper Therapeutics, Inc. (NASDAQ:JSPR) for alleged federal securities law violations. The lawsuit claims that Jasper made materially false and misleading statements regarding its manufacturing contro", "url": "https://natlawreview.com/press-releases/jspr-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-jasper", "source_name": "The National Law Review", "published_at": "2026-06-29T14:39:44", "published_display": "29 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Jasper Therapeutics, Inc. \u2013 BOATS:JSPRW", "summary": "This article provides the \"price to earnings forward\" value for Jasper Therapeutics, Inc. (JSPRW). It focuses solely on this financial metric without offering additional analysis or context. The content is presented within the framework of financial data provided by TradingView.", "url": "https://www.tradingview.com/symbols/BOATS-JSPRW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:40:19", "published_display": "26 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Stock - Analyst consensus and weekly review", "summary": "This article provides an analyst consensus and weekly review for Jasper Therapeutics (JSPR), a speculative small-cap biotech. It highlights the company's \"Buy\" rating profile from analysts, despite its early-stage pipeline and limited revenue, focusing on future clinical mileston", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/jasper-therapeutics-stock-analyst-consensus-and-weekly-review/69586016", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T23:01:35", "published_display": "19 Jun 2026 23:01", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPRW) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article from TradingKey analyzes the financial health of Jasper Therapeutics Inc (JSPRW) by examining its profitability and balance sheet. However, the report notes that relevant financial data for key metrics such as cash and cash equivalents, total assets, total liabilitie", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jsprw/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T11:40:19", "published_display": "19 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Jasper Therapeutics Inc (JSPR), including analyst ratings, target prices, and EPS expectations. Based on 8 analysts, the stock has a \"Buy\" rating with a target price of $10.50, representing a significant upside. The company's previou", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T09:10:35", "published_display": "19 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Institutional Confidence", "summary": "This article provides details on the institutional confidence for Jasper Therapeutics Inc (JSPR), including top institutional shareholders and changes in their holdings. Key holders like Velan Capital, Morgan Stanley, and Millennium Management are listed with their share counts a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T02:40:50", "published_display": "19 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Jasper Therapeutics Inc (JSPR), focusing on key financial metrics like P/E, P/B, P/S, and P/CF ratios. The report indicates that relevant data for these metrics have not yet been disclosed by the company. It also includes current sto", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T01:40:51", "published_display": "19 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPRW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Jasper Therapeutics Inc's (JSPRW) dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years and currently shows no records of stock split events. The current stock price ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jsprw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:39:39", "published_display": "18 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPRW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Jasper Therapeutics Inc (JSPRW), showing a previous score of 0.00 with no change. It lists several institutional shareholders and their shareholdings, including changes in their positions. The primary focus i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jsprw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:19", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Jasper Therapeutics Inc's (JSPR) dividend and stock split history. It notes that the company has not distributed dividends in the past five years and details a 10-to-1 merger-related stock split that occurred on January 2, 2024. The stock info", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-jspr/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T08:10:51", "published_display": "17 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 virtual meeting, board and pay votes", "summary": "Jasper Therapeutics (JSPR) will hold its 2026 annual stockholder meeting virtually on July 31, 2026. Key proposals include the election of two Class II directors (Judith Shizuru and Tom Wiggans), ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026, and ", "url": "https://www.stocktitan.net/sec-filings/JSPR/def-14a-jasper-therapeutics-inc-definitive-proxy-statement-e0b6f5fee069.html", "source_name": "Stock Titan", "published_at": "2026-06-15T20:39:31", "published_display": "15 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Receives Nasdaq Minimum Bid Price Notice", "summary": "Jasper Therapeutics (JSPR) has received a Nasdaq notice for falling below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 days, until November 30, 2026, to regain compliance, with its stock continuing to trade without immediate impact. Failure to", "url": "https://www.theglobeandmail.com/investing/markets/stocks/JSPR/pressreleases/2409077/jasper-therapeutics-receives-nasdaq-minimum-bid-price-notice/", "source_name": "The Globe and Mail", "published_at": "2026-06-10T15:56:00", "published_display": "10 Jun 2026 15:56", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value", "summary": "Jasper Therapeutics, a clinical-stage biotechnology company, has announced that its Board of Directors is initiating a comprehensive review of strategic alternatives to maximize shareholder value. These alternatives include potential asset sales, licensing, collaborations, a comp", "url": "https://www.globenewswire.com/news-release/2026/6/1/3304277/0/en/jasper-therapeutics-announces-exploration-of-strategic-alternatives-to-maximize-shareholder-value.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T05:11:13", "published_display": "10 Jun 2026 05:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deal Dispatch: Jasper Therapeutics For Sale, RobinHood Completes $180 Million WonderFi Acquisition, Long John Silver's Franchisee To Liquidate", "summary": "This \"Deal Dispatch\" article covers recent M&A activities and company news, including Jasper Therapeutics exploring strategic alternatives, private equity firm New Mountain Capital acquiring Asset Living for over $2 billion, and Robinhood's completion of its $180 million acquisit", "url": "https://www.benzinga.com/m-a/26/06/53036552/deal-dispatch-jasper-therapeutics-for-sale-robinhood-completes-180-million-wonderfi-acquisition-long-john-silvers-franchisee-to-liquidate", "source_name": "Benzinga", "published_at": "2026-06-05T17:09:55", "published_display": "05 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNNDdwUjdOeTJJcG1MQ2Nlc0w1V3oyRFRQT3JCRzZ6WjZMR2lRZnpkNFFqVlB4ZkFFX0VzdWJXM3B1ZVptWE9UVndYLWQ0NkxQQW4yWC0xXzljTXNrMW04WlMzcldEWUluZUpMSlVlbFotMzJ2b2Y1TE1Td1VHU19fd0llZGh5d2E0eWdoMGJ2RnRXQ0lEanlCaUZJeGlMZw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Initiates Strategic Alternatives Review to Maximize Shareholder Value Amid Mast Cell Disease Therapy Focus 1", "summary": "Jasper Therapeutics (Nasdaq: JSPR) has launched a strategic review to explore options such as asset sale/licensing, collaborations, company sale, mergers, or an orderly wind-down, aiming to maximize shareholder value. The company will also implement cost-saving measures and conti", "url": "https://www.minichart.com.sg/2026/06/01/jasper-therapeutics-initiates-strategic-alternatives-review-to-maximize-shareholder-value-amid-mast-cell-disease-therapy-focus-1/", "source_name": "Minichart", "published_at": "2026-06-01T15:47:00", "published_display": "01 Jun 2026 15:47", "sentiment": "negative", "sentiment_pct": 39, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Explores Sale, Merger and Other Strategic Alternatives", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jasper-therapeutics-explores-sale-merger-124908303.html", "source_name": "MT Newswires", "published_at": "2026-06-01T12:49:08+00:00", "published_display": "01 Jun 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Jasper Therapeutics weighs options from asset sale to wind-down", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQT1NkZ0ttTDRuNlN4ZWlBRk9ZYzVITXkzRERxMC1wYmlPaW5LOXFIUkZjUkFDZEY0YWpxMUg5S2pfdTdKRGprZmlyc1lxblYwODB4c3g5d3h6cnpXMEh6WEU4Z2stbFRGVmhyXzNmZWtNdFFyRXAwd3A3T0ZxS2dzQmMxRFB2VDMweE9EY3hBbjdNbkNabG5UeTNaWDl4Y2xGUUJUWWQtNldKa0dOUFRiTk9IUHdWM2U4U05uUEVSNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics explores strategic alternatives", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQY0ZkX1JwdVJkQVZVMUpOS2k5a3Nad0Y2UTVIb1Rob2x4OHFRc0hVQ2NPelEzZ0lpbC1YMjBNZF9YN1ZfQ1pwWjhkejBhOEhpdDdwb3ZKZ2lDU2llR1dha3JhenRqaHlZTGhYdU43TWFHSXZxcEhRc1l4SkhwRFJaamthVFZxTzd3REJMOW1SRG5jTDRJbndJU1hhM0hJSUpsMnAxS096bHF1QjRH?oc=5", "source_name": "Investing.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Cuts Price Target on Jasper Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-cuts-price-target-jasper-115804345.html", "source_name": "MT Newswires", "published_at": "2026-05-15T11:58:04+00:00", "published_display": "15 May 2026 11:58", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Downgrades Jasper Therapeutics to Hold From Buy", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/td-cowen-downgrades-jasper-therapeutics-112203153.html", "source_name": "MT Newswires", "published_at": "2026-05-15T11:22:03+00:00", "published_display": "15 May 2026 11:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $9.08, Implies 847% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPa1B4RnZpbnU1bkRLb29OSTdOaDI1ZW52d3d1SjRLcGNQSjhRQ2NZeGJqTlhlcnZFMkQxRW44R0w1Mi03Mm1JVFlVdGRmbHAwVEtkTlR2d0I2MGNwOGkxZlAwQjIwU2tvSzBxbjFlOV9ZbGtIMFRXRDk4ZUVERk02MDFLa1ZxQ0EwME5oZGkxRk13SnNJTXFwN0gyVlZhMDVWQ3gza1I5TWNMSGtHbm01UUd5RFVJWkt3a0dPY3A0N1pPamJ3Y1pZTnRTdTVGWFdQd0wtTEFuRFBuVVRQ?oc=5", "source_name": "TradingView", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/jasper-therapeutics-reports-first-quarter-200500117.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVWkybk56d1cyQm5xdF95eWc4QTcxSmdqLVh4YXZwLUxXNzg2UDVCbDdQQWU3UlNfakhJZ1hJb1Ywb2JkTDhReXVkQ0tWeFc0XzlDdWo5SUdqd2V3OHVoZlVma2s2YUE1RnI0akZEdmsxNEZMdTJaZkl6OEJNcE1UWkYzaU5kelVBcmRiNmtqNWZ3Y0VSdXZseGpCV0xhem9xTEVV?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens reiterates Jasper Therapeutics stock rating on CEO change", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNUzBadkpycVRraDB6dTNrZDVXMnJ1bVhrZnYxU0FIZTZ0THcwZWhtNzctc3VEMk1hVlhCYmNONjIzb2UxSGpJOXFFRGlMZjduWDhiN2VJZ3ZyMXc4QnlNUk4tVG0wc1JYdHNhSVZ1MUppY2taWkRtNm5NdGYxWG5LWVozVV9PRTdaU3ljSEl2bnlKNGQzRHpXR3IwTHk5VV91cURyOU1pLWdQTzliRUJ5MG8xSGVXeTc5M0ZLSGVKSkRCc0ND?oc=5", "source_name": "Investing.com", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPbWcybXJ4aHcwRlRhZThtX2R4Y3NqSk1JbHpHbllKVERwQWhDZGRsdURZVXFJUVp2LUtJX2o2V2JUNWNhQXhFWktRQy0taDZRVG9pUTZvSmc0NkU2QWcwMkJGYkFfS01EZlVPQjNyUlV4dWNzZ3JzUWdCOTNlV0swdktsdGRpUmc5WG5iakYwbHJsUDVCLUIyUTdDak94d2c1aTdhZTNDS3Q1eThucUxIRg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPTk45cFpkTlIyZFp6dmxjQjBTNGtJa2VGcTVWUTEtLVIzUVQ3d2k1bW1uSFJYc2xjMExaRWQ5UWhOUGI3QWkyQVg0TldlalAxZVQ3TDdMdnF2YzBOeGE3ZkNVTk4xQWEwV1NWc1BIMjZBNms2cE5uZHdzd05HcWh4eVVNYy1NZTVCX0FnYUppNndWM2JTMWZ2RzJsbDg3SF9NdEVBT0pZQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow (NASDAQ:JSPR) 2026-01-11", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNcGxnbVhtM0pCV09iWVNaR1RMOEcxd0M0T0VMVjNwMDh2TW1qalIzRldUb21USjdxcG9ZS2NnUHpIWnA5cGROR0NnZ1dhTC1zTnVXQVZOZmNpbjhpQ2ZwVFlUU0kxcVhsZE1aanZtR3J2OFBULU90TnRXYXZmLXRfaXUyd1VSMHdTTk1lOXU3NGJURzR3VzhQYTR1NG52bEhUeGdSRmVjdzhUQnNTZEdKREc4YW9ObjRNOWFPUnVKVW9PWVNZQkJLOQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPT1RfTnBld0hDZ0hMcEN4bnBSQk5oMkJzQjFlVGg0TGdPNUlQR0l1YWZPemVKT0xJVXFTU1NyT1VXdkxxV1N1UG14bW1qTUJzbHhNTkVfQks0VWJ2eldpZ1dQZTJDRUVJc09wa3JITG5PcnJXRXFVX1lHcHh5YWxfNFpLRUczeEQwT28wcmxENngtWGhnZzlVakZJVWx5eXpjRTctRENERHZCYWUwYVMwUWVwMWQ0MGZNXzRROWJmTk5JdmRGMlJ3bUF1cy1iVDB3NFdPYXo1WlVSVnpNQTU1YVJuR2F4cFBB0gHuAUFVX3lxTE42cURzcDVQVzRIWjJKZXVtenoxbExMV3I4MFRPTmdyMGlRaGU3V0FkdnJYaVNYX0tLMDB2X3FUcjUtbmtsa05jZE4zYXF1ZTFuaUJXekQ1YThRa09kR3VfZUgwUnktREJjR0sxQkhxUmR3XzFwQzR2RHdFMXRMdlA5VzVENXdheGF4UWVHbkZOb0RoV1U0dEZZdkF5bHE2V3pLaTh6dXBSd0FCTlNPcFR0a3ZUYXVNc0JTTDdYdU40MFg4eGR2Qm5YeEw2OHctMVRTWk5ZNElLU2NyOV9tLXNxZk43OEhoS1NmQ1JGS3c?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxQMmx1cFZ3YXV2cHlKeFk5RGlwZHhxODdOeXFsYTk0TE1zaXRFQ3RZRVUtV28wUzI0ckQ0UVBPaVh4RTgwX1pRNE9mRXFOR1FWcGJsMHVaT2dfeU5nTzZ1U200blJRLTBxOGN5S3BqMXo5Ull0ZVEwQXlQZ3dNSlBQX1pST3BBd2ZkODFsZ09CWUllSF9iT3BzWjRjbzdQd2ZUNU5GR2lMcUVtMHhnbkJmYy0xSXdacXJxbkRSbS1VMll4WHNEeWhfRHNtcGt4NWJIM25zSXpneUlpYVptWEZacjlVSGd1UmhLc01vMXpPejFFUWtYR1pmbWZoWExaSFdsUnNfTA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics Faces A Funding Crunch Before Its Next Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE41QzVmaFpPQ0xKa0xPMnBBRTNfeWRRVzAyMWJlQk5WRFZHeWVucjYzX1l3SkFpc0pEd215SlVhVzk1MWk1OUtoN1poQ2dfVWdGN1Z1M0FpczZURTgx?oc=5", "source_name": "Finimize", "published_at": "2025-12-04T14:29:34+00:00", "published_display": "04 Dec 2025 14:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNOXp3OXIyMDVIdVFXaEZ3anEzUEhCV1d4UnZnOXdoTmR1T3ZVVkVCc29pemlUWVNLaTE3U1pGUmg2ajBtM04xcEdPMlFKZ2IwQ1F3dUxtTm5pb3FnX0FnY3BfMFFiRUR2Zng5SkZ1Vk5kUkJhZlJjWlM5R1RrNFBwNWRzVlhxUzM5cmRJQnBUdExGcGFZVGwxcXlQYTNQNkdnbFYzRHhqT2ZWOWhRWElSWGRCQWdOSlRWTjJ6aGhMZDdKbmpEYW4xVi1RNlB4blFvc1BXeXY1algzVFI5eFlsTnJieUxzc1lBZjhrdTNGZlRCc3hhUll1UTNQd0htczNIVmc?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics falls after $30 mln stock-and-warrants deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNVS00SDJVZVdRTmZiV1Bybms2V3l0RzlDM05EdUtveUtTR20tZmxUaHpZQ2J6WEFoT3Y3VEhHUUdGWVdmU2preEF2QW9VZDIyRXl2dG9MbWluLTZxb2UxNVVIblEzREloS0VoblBEemlCX25kS3E1d1NqZEhnRFpkblZjeVlVZlRFUmxZQ2JnaWVjQWhwUW96YXFiTXdtMEt3M0RORUZmelM0ZUVNSm9PeGk3RGE1bG1nRFBTT2hRWmc4SnA2YzI0Ql9ncnI?oc=5", "source_name": "TradingView", "published_at": "2025-09-19T07:00:00+00:00", "published_display": "19 Sep 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics (JSPR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE4zc0NUNVB0dU95ZHRFRG1tVE9NTWxkNmJxaHl5c2pjZndYZ0tzS0UtTWd4OVhiTmJEOXppQ3ljcEZUZ3lKOXRLZFBTRUVhWWJmVGpz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:34:25+00:00", "published_display": "25 Apr 2025 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jasper Therapeutics (JSPR) Stock Price, News & Analysis $JSPR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1GVHpSWXNpd2hxRTBEMm10c09UZ1JHV05yX2FhMXVDTGZYT2ZwMkhzVkc0MVo1SXFSSUsxMHllcjE1dldJY0prVUJjbEJ0TmFPT0pTcUlGYU9qdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-09-30T11:53:08+00:00", "published_display": "30 Sep 2021 11:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 56, "sentiment_summary": {"positive": 6, "negative": 10, "neutral": 40, "score": 48, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 0.58, "latest_week": "2026-07-10", "one_week_move": 35.3, "four_week_move": 26.6, "twelve_week_move": -43.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.068244, "market_dynamics_buy_signal": false, "relative_strength": -70.683392, "fair_value_gap": -94.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.2403, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+35.3% over one week, +26.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 9}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "AD HOC NEWS", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+35.3% over one week, +26.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Jasper Therapeutics (NASDAQ: JSPR) sees Millennium group report 1.7% equity stake"}], "updated_at": "2026-07-16T05:28:34.823049+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}